27 October 2022 in International Journal of Dermatology
PRPattareewan Rojanapanthu
4 January 2023 in Dermatology
Background: Drug patch test to identify cutaneous adverse drug reactions (CADRs) has been widely reported. Appropriate vehicles can improve the ability of drug delivery and significantly increase positive reaction of drug patch tests. Objective: The aim of this study was to evaluate the efficacy of drug patch tests using 0.9% saline vehicle in comparison with other traditional vehicles in CADRs. Method: All patients were patch tested with suspected drugs using 10–30% concentration of the commercialized form of drugs diluted in 0.9% saline, petrolatum, and water. Result: Of 100 patients with CADRs, 54 of those had at least one positive drug patch test. In terms of vehicles used, 43 patients had positive drug patch test with saline as compared to 35 with water (p = 0.485) and 25 with petrolatum (p = 0.007). Among CADRs subgroup, saline rendered significantly higher positive rate when compared with petrolatum in drug rash with eosinophilia and systemic symptom (DRESS) (70% vs. 20%, p = 0.025), maculopapular rash (MP) (52.4% vs. 31%, p = 0.046), and lichenoid drug eruption (46.7% vs. 0.0%, p = 0.002). 12/54 (22.2%) of CADRs patients had positive reaction with saline alone. Among these patients, 4/12 (33.3%) were lichenoid drug reaction, 3/12 (25%) were DRESS, and 2/12 (16.7%) were MP rash. Allopurinol was the drug giving positive patch test only with saline. Conclusion: Appropriate vehicles are essential to obtain the positive drug patch test. Using saline as a vehicle can increase the positive reaction of drug patch test, particularly in lichenoid drug eruption. We recommend the use of saline as another traditional vehicle in drug patch test.
15 November 2023 in Experimental Dermatology
26 November 2021 in Scientific Reports
Gonococcal urethritis (GU) is the second most common sexually transmitted infection (STI). Epidemiologic studies of the situation of GU reinfection and its related risk factors among patients with a history of GU in Thailand remain somewhat limited. A hospital-based retrospective cohort study was conducted between January 1, 2010 and December 31, 2020 to determine the incidence and risk factors of GU reinfection among male patients visiting in Royal Thai Army (RTA) Hospitals. A total of 2,465 male patients presenting a history of GU was included in this study. In all, 147 (6.0%; 95% CI 5.1–6.9) male patients presented GU reinfection, representing an incidence rate of 1.3 (95% CI 1.1–1.5) per 100 person-years. The independent risk factors for GU reinfection were age < 30 years (AHR 1.7; 95% CI 1.0–2.8), number of sexual partners equal to 2 (AHR 3.4; 95% CI 1.0–11.2), $$\ge$$ 3 (AHR 5.6; 95% CI 2.7–11.6), and participants residing in the north (AHR 4.1; 95% CI 2.3–7.5) and northeast regions (AHR 2.1; 95% CI 1.1–3.9). Incidence of GU reinfection among male patients visiting RTA Hospitals was significantly high among younger aged patients, especially in the north and northeast regions. Multiple sex partners played a major role in GU reinfection. Effective STI prevention programs should be provided to alleviate reinfection and its complications.
5 November 2026 in Asia Pacific Allergy
Background: Telemedicine has become an essential tool in healthcare, providing an alternative platform for managing chronic diseases. While telemedicine has shown patient satisfaction in general dermatology, limited research has focused on its effectiveness and satisfaction specifically for chronic spontaneous urticaria. Objectives: The study aimed to compare disease activity and quality of life in chronic spontaneous urticaria patients managed via telemedicine versus in-person visits and to assess patient satisfaction with telemedicine. Methods: A prospective study was conducted with 50 chronic spontaneous urticaria patients, equally divided into telemedicine and in-person groups. Disease activity and control were evaluated using the Urticaria Activity Score 7. Quality of life was measured using the Thai Chronic Urticaria Quality of Life Questionnaire, and satisfaction was assessed using the Telehealth Usability Questionnaire. Results: At baseline, the mean Urticaria Activity Score 7 was 11.68 ± 9.19 in the telemedicine group and 7.60 ± 7.69 in the in-person group ( P = 0.095), with 11/25 (44.0%) and 14/25 (56.0%) achieving disease control, respectively ( P = 0.396). After 24 weeks, disease control was observed in 24/25 (96.0%) in the telemedicine group and 20/25 (80.0%) in the in-person group ( P = 0.189). Comparable improvements were observed in Thai Chronic Urticaria Quality of Life Questionnaire ( P = 0.806). Satisfaction with telemedicine was high, with a mean Telehealth Usability Questionnaire score of 4.66 ± 0.26. Conclusion: Telemedicine is a feasible and effective alternative for the management of chronic spontaneous urticaria, providing disease control and quality of life improvements that were noninferior to in-person care, with high patient satisfaction.
1 January 2026 in Dermatologic Therapy
Background: Drug patch testing was affected by multiple influencing factors. HLA allele‐associated drug allergy was mentioned as one factor influencing drug patch testing. We aimed to evaluate the correlation between drug patch test and HLA alleles in patients with cutaneous adverse drug reactions. Methods: The study enrolled 30 patients, who had drug patch testing, to evaluate HLA alleles. We compared HLA alleles between patients with positive and negative patch test results and between those with positive patch tests and the Thai general population. Results: Among the 30 patients, including 20 positive patch test patients and 10 negative‐patch test patients, a distribution for males (50%) was observed, with a mean age of 55.4 ± 15.5. The most prevalent cutaneous drug reactions in patch test‐positive patients were morbilliform drug eruption 8/20 (40.0%) and fixed drug eruption 7/20 (35.0%). NSAIDs and antibiotics were the dominant culprit drug groups. These groups account for 5/20 (25.0%) and 4/20 (20.0%) of patients, respectively. None of the HLA alleles was significantly identified in patients with positive patch test compared to patients with negative patch test. However, HLA‐B ∗ 54:01 and HLA‐C ∗ 07:01 were significantly associated with patients who had positive patch test results for NSAID‐induced minor drug reactions when compared with the Thai general population ( p ≤ 0.0001), with odds ratios of 34 and 10, respectively. Conclusion: In this small pilot study, HLA‐B ∗ 54:01 and HLA‐C ∗ 07:01 alleles showed a preliminary association with positive patch test results in patients with NSAID‐induced minor drug reactions. We hypothesized that HLA alleles might influence the positive patch test reaction.